Overview
Aleva Neurotherapeutics is a Swiss medical device company developing directional deep brain stimulation leads for Parkinson's disease and other movement disorders. Their directSTIM technology enables highly targeted stimulation to maximize therapeutic benefit while minimizing side effects.
More in Brain-Computer Interfaces
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
🧠 Brain-Computer Interfaces
Location
Lausanne, Switzerland
Funding
Series C · $35M
Website
aleva-neuro.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →